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ABSTRACT
Background: Adults admitted to hospital with community-acquired pneumonia (CAP) impose signifi-
cant burden upon limited hospital resources. To achieve early response and possibly early discharge,
thus reducing hospital expenditure, the choice of initial antibiotic therapy is pivotal.
Methods: A cost-consequences model was developed to evaluate ceftaroline fosamil (CFT) as an alter-
native to other antibiotic therapies (ceftriaxone, co-amoxiclav, moxifloxacin, levofloxacin) for the
empiric treatment of hospitalized adults with moderate/severe CAP (PORT score III–IV) from the per-
spective of the Spanish National Health System (NHS).
Findings: Compared with ceftriaxone, the model predicted an increase in the number of CFT-treated
patients discharged early (PDE) (30.6% vs. 26.1%) while decreasing initial antibiotic failures (3.8% vs.
7.6%). For patients with pneumococcal pneumonia, CFT was cost-saving vs. ceftriaxone (by 1.2%) and
significantly increased PDE (32.1% vs. 24.6%). CFT resulted in cost-saving vs. levofloxacin, due lower
initial antibiotic therapy costs and increased PDE (30.6% vs. 14.9%). Moxifloxacin and co-amoxiclav
early response rate of 53.63% and 54.24% resulted in cost neutrality vs. CFT, with direct comparison
hampered by the significantly different early response criteria utilized in the literature.
Conclusions: Despite a higher unit cost, CFT is a reasonable alternative to other agents for adults hos-
pitalized with moderate/severe CAP, given the projected higher PDE achieved with similar or lower
total costs.
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Introduction
Community-acquired pneumonia (CAP) remains an acute
infection with significant associated morbidity, mortality and
economic burden1–4, particularly prevalent in the elderly.
Indeed, within an estimated European incidence of 0.2–242
per 1,000 adults/year, significantly higher rates are observed
in the elderly population3,4. Accordingly, in the US, 1.3 mil-
lion cases of CAP were estimated to have occurred in adults
65 years in 20125. With the globally aging population, the
incidence and burden of CAP is therefore set to increase
even further3,6,7. One study in primary care showed an inci-
dence of CAP in Spain that was in the range 4.63/1,000 peo-
ple/year4. The incidence in people older than 65 years was
higher in men, with a range of 7.06–36.93 compared to
5.43–19.62 in women.
Although mild disease can be managed in the commu-
nity, a significant proportion of patients with comorbidities,
such as metabolic or cardiovascular disease, or more severe
CAP will require hospitalization8. The medical costs
associated with each episode of inpatient care for CAP was
estimated to exceed $18,000 in the US in 2012, which equa-
ted to an overall annual burden above $13 billion5,6.
Similarly, in Europe, the estimated inpatient care direct costs
amount to e5.7 billion per year with a further estimated e3.6
billion of indirect costs due to productivity loss3. Given that
the main determinants of overall costs are in-patient treat-
ment, hospital length of stay and the need for intensive
care3,9, effective treatment which can achieve rapid clinical
cure and enable early discharge are therefore highly desir-
able. Furthermore, the rising concern of antibiotic resistance,
which has been observed in all pathogens associated with
CAP3, also necessitates alternative effective treatments.
A series of well-established guidelines govern the treat-
ment strategy, with the aim of reducing unnecessary hospi-
talization and readmissions, length of hospital stays,
mortality and in turn cost10–12. Upon admission, most
patients are treated empirically with antibiotics selected
according to disease severity, local patterns of bacterial
resistance and safety profiles1. As initial antibiotic treatment
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failure has been shown to prolong hospital stay, increase
antibiotic usage and add to hospital expenditure, this is a
pivotal decision13. The most common antibiotic approach
involves monotherapy with a respiratory fluoroquinolone or
combination therapy with a macrolide plus a b-lactam14,15.
Ceftaroline fosamil (CFT) is a fifth-generation cephalo-
sporin with a broad spectrum of antibacterial activity. In an
integrated analysis of the two pivotal, multicenter, phase III
RCTs trials (FOCUS 1 and FOCUS 2), CFT treatment was non-
inferior to ceftriaxone in adults with CAP (Pneumonia
Outcomes Research Team (PORT) risk class III or IV)16.
Specifically, CFT demonstrated numerically higher clinical
cure rates than ceftriaxone in the clinically evaluable popula-
tion both in the individual trials (FOCUS 1: 86.6% vs. 78.2%,
FOCUS 2: 82.1% vs. 77.2%) and in the combined analysis
(84.3% vs. 77.7%)16. Furthermore, when the trials data were
analyzed focusing on the early response (Day 4, 72–96 h, CFT
appeared to provide clinical benefit over ceftriaxone at Day
4, with Day 4 clinical response rates of 69.5% vs. 59.4%17. In
addition, real-world studies have shown CFT to be effective,
irrespective of whether it was used as monotherapy or con-
current therapy18, first- or second-line therapy18,19, in elderly
patients18,20 or in patients with significant comorbidities20.
As newer agents, such as CFT, become available, the num-
ber of treatment options open to clinicians, will increase.
However, given the rising concern of national health system
expenditures, decisions need to be made based on economic
value as well as clinical benefit. Focusing on Spain, between
2004 and 2013, the hospitalization rates for CAP in Spain
increased significantly from 142.4 to 163.87 cases/100,000
inhabitants21. This study was therefore undertaken to evalu-
ate intravenous (IV) CFT (600mg q12hr) as an alternative to
available IV antibiotic therapies for the empiric treatment of
hospitalized patients with moderate/severe CAP from the
perspective of the Spanish National Health System.
Methods
Model structure
A decision-tree model was developed in Microsoft Excel 2016
(Microsoft Corporation, Redmond, WA), to simulate the clin-
ical pathway of a hypothetical cohort of adult patients
admitted to hospital in Spain with moderate/severe CAP
(PORT score III–IV) tracking the costs and consequences of
treatments as shown in Figure 1. Upon admission, the initial
decision was to either treat with CFT 600mg every 12 h
(q12hr) or an alternative antibiotic. The alternative antibiotics
included in the analysis were ceftriaxone 1–2 g every 24 h
(q24h), co-amoxiclav 1.2 g every 8 h (q8h), moxifloxacin
400mg q24h or levofloxacin 0.5–1 g q24h, based on CAP
guidelines and clinical expert consultation10–12.
Patients initially receive intravenous (IV) antibiotic therapy
for four days before clinical and microbiological assessment.
After 4 days, responding patients17 will either switch to a
5-day course of oral antibiotics and be discharged early, or
remain in hospital due to conditions unrelated to pneumonia
(e.g. unable to swallow), and continue to receive IV antibiotic
therapy22. Non-responders after 4 days will either remain
on IV therapy until clinical cure and discharge or switch to a
second-line antibiotic (e.g. ceftriaxone) until clinical cure
and discharge23. The non-responders switched to a second-
line antibiotic could either be treated in the general ward
or in an intensive care unit (ICU) and then switched to the
general ward.
Figure 1. Schematic visualization of the decision-tree model. Over each branch, a brief description of the corresponding patient pathway has been summarized.
Abbreviations. CAP, community-acquired pneumonia; ICU, intensive care unit; IV, intravenous.
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This model structure was considered most appropriate
since costs and clinical outcomes (resolution of signs and
symptoms of the infection) occur over a relatively short
period of time, typically <3weeks from hospital admission to
discharge24.
Model inputs
Clinical efficacy inputs
The clinical inputs used in the cost-effectiveness analyses are
summarized in Table 1. The clinical cure rate for CFT was
obtained from an integrated analysis of phase III trials16, and
in the absence of head-to-head data, the clinical cure rates
for the other antibiotics were estimated from a published
network meta-analysis (NMA)25. Accordingly, the relative risk
(RR) of CFT versus ceftriaxone, co-amoxiclav, levofloxacin and
moxifloxacin were reported to be 1.10 (95% confidence inter-
vals [Cl] 1.04–1.16), 1.18 (95% Cl 1.06–1.3), 1.05 (95% Cl
0.96–1.15) and 1.08 (95% Cl 0.99–1.16) respectively.
Day 4 clinical response was based on criteria set by the
FDA and was defined as meeting criteria for both clinical sta-
bility and clinical improvement on Day 4:
 Clinical stability was defined according to the Infectious
Diseases Society of America/American Thoracic Society
guidelines as temperature <37.8 C, heart rate <100
beats/min, respiratory rate <24 breaths/min, systolic
blood pressure >90mmHg, oxygen saturation >90% and
confusion/disorientation (recorded as absent).
 Clinical improvement was defined as improvement of at
least one of four symptoms present at baseline (i.e.
cough, dyspnea, pleuritic chest pain, sputum production)
with worsening of none.
Patients who did not meet both criteria were considered
non-responders.
Day 4 clinical response rates, sourced from a post hoc
analysis of the FOCUS trials in the CE population17, were
69.5% for CFT and 59.4% for the ceftriaxone. Focusing on
the pneumococcal pneumonia confirmed group, the clinical
response rates at Day 4 were 73.0% in the CFT group and
56.0% in the ceftriaxone group. The values for the other
comparators are summarized in Table 1 along with the corre-
sponding references.
It is important to notice that the moxifloxacin early
response criteria utilized in the literature were significantly
different to those utilized for CFT, with early response
defined as just body temperature <37.5 C27. Similarly, early
response criteria for co-amoxiclav were less stringent than
the criteria used for CFT (improvement in two out of four
CAP symptoms, clinical stability not required)28. Therefore,
comparison against moxifloxacin and co-amoxiclav was ham-
pered by the lack of comparable early response data in the
literature. Nevertheless, threshold analysis was performed for
both co-amoxiclav and moxifloxacin to assess the level of
early response rate at which cost-neutrality could be
achieved with respect to CFT.
Economic inputs
Health care resource use and costs are shown in Table 2. The
average hospital length of stay (LOS) for patients both
responding to and failing on initial antibiotic therapy, as well
as the associated admission rates to and duration of stays in
ICU for the latter patients was obtained from a large obser-
vational study of CAP management in hospitalized patients23.
A prospective observational study of 200 patients with CAP
admitted to hospital provided the proportion of treatment
responders (44%) eligible for iv-to-oral switch and early hos-
pital discharge22. The duration of first-line antibiotic treat-
ment was assumed as 6.6 days for CFT and all comparators,
consistent with the duration observed in the CFT trials16.
Ceftriaxone monotherapy was selected as the second line
antibiotic of choice for patients treated in general wards, fol-
lowing clinical experts’ consultation, while a combination
therapy (ceftriaxoneþ azithromycin) was deemed more suit-
able for ICU patients. The duration of second line antibiotic
treatment was assumed to be 7days, due to lack of reliable
sources found in the literature but varied during the sensitiv-
ity analysis.
Ceftriaxone 1 g q24hr and levofloxacin 500mg q24hr dos-
ages were used for the base case as these were the doses
used in the source clinical trials. However, higher doses are
routinely needed in real life to achieve similar efficacy to
that observed in clinical trials. Additional scenarios with
Table 1. Clinical inputs for the cost-effectiveness analysis.
Description Base-case SE Distribution Source
Probability of clinical cure with CFT
Probability of clinical cure with CFT in pneumococcal pneumonia
0.843
0.855
0.0170
0.042
Beta
Beta
16
Relative risk clinical cure CFT vs. ceftriaxone
Probability of clinical cure with ceftriaxone in pneumococcal pneumonia
1.10
0.686
0.028
0.052
LogNormal
Beta
16
25
Relative risk clinical cure CFT vs. co-amoxiclav 1.18 0.05 LogNormal 25
Relative risk clinical cure CFT vs. levofloxacin 1.05 0.05 LogNormal 25
Relative risk clinical cure CFT vs. moxifloxacin 1.08 0.04 LogNormal 25
Probability of Day 4 clinical response for CFT 0.695 0.0371 Beta 17
Probability of Day 4 clinical response for CFT in pneumococcal pneumonia 0.73 0.0516 Beta 17
Probability of Day 4 clinical response for ceftriaxone 0.594 0.0394 Beta 17
Probability of Day 4 clinical response for ceftriaxone in pneumococcal pneumonia 0.56 0.0567 Beta 17
Probability of Day 4 clinical response for co-amoxiclav NA NA NA
Probability of Day 4 clinical response for moxifloxacin NA NA NA
Probability of Day 4 clinical response for levofloxacin 0.34 0.046 Beta 26
Abbreviations. CFT, ceftaroline fosamil; NA, not applicable; SE, standard error.
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ceftriaxone 2 g q24hr and levofloxacin 1 g q24hr were simu-
lated to reflect the doses most commonly used in clinical
practice. Drug and hospital resource costs were sourced from
the Spanish national price list 2017.
Model assumptions
When building the decision-tree model, multiple assumptions
had to be made to simplify the clinical pathways and allow
data from multiple sources to be integrated. Firstly, the early
response rate across trials was assumed to be comparable.
Secondly, the duration of IV treatment in patients remaining
in hospital beyond 4 days was assumed to be the same for
CFT and all the comparators considered, due to the lack of
treatment specific data published in the literature16. Thirdly,
as the costs of initial microbiological testing, and concomi-
tant antibiotics providing coverage against atypical patho-
gens were assumed to be the same in both treatment arms,
these were not considered in the model in the base case
(consistent with the clinical trial protocols from which the
efficacy inputs have been derived). Nevertheless, one add-
itional scenario was tested adding concomitant macrolide
therapy (azithromycin 500mg q24h – first 3 days IV then oral
formulation for a daily cost of e7.31) to each beta-lactam
treatment (ceftaroline fosamil, ceftriaxone, co-amoxiclav) as
recommended in the latest clinical guidelines and likely hap-
pening in clinical practice14,15.
Model analyses
The model predicted health outcomes such as percentage of
patients discharged at Day 4, percentage of patients experi-
encing antibiotic treatment failure, and percentage of
patients treated in the ICU, as well as incremental costs of
CFT versus each of the comparators were included in the
analysis. Furthermore, sub-group analysis focusing on the
pneumococcal pneumonia confirmed group was performed
for CFT versus ceftriaxone, given the high-mortality associ-
ated with this specific causative organism3. Due to lack of
data a pneumococcal subgroup analysis was not possible for
the other comparators.
Deterministic one-way sensitivity analysis was performed
to identify the primary sources of uncertainty in the model’s
estimates of treatment costs and clinical outcomes. The
model base-case inputs were varied within their 95% CIs,
obtained from assigned statistical distributions as specified in
Tables 1 and 2 (beta-distribution for probabilities, and log-
normal distribution for relative risks) while the costs were
varied by ±25%.
In additional, probabilistic sensitivity analysis (PSA) was
undertaken to assess the impact of simultaneously varying
clinical outcomes and health care resource use with respect
to the model outcomes, using Monte Carlo simulation (1,000
simulations were performed).
Results
Compared to ceftriaxone-treated patients, a higher percent-
age of CFT-treated patients were predicted by the model to
be eligible for early discharge (30.6% vs. 26.1%; Figure 2),
and fewer were projected to experience initial antibiotic fail-
ure (3.8% vs. 7.6%) or require ICU treatment (0.9% vs. 1.9%)
(see Table 3). The predicted total average costs of CFT were
e286.10 per patient higher than ceftriaxone (1 g q24hr),
resulting in a 5% increase (Table 4 and Figure 2). Specifically,
CFT patients were projected to have higher initial antibiotic
drug costs and oral step-down costs versus ceftriaxone.
Similar results were obtained when ceftriaxone 2 g q24hr
dosage was compared, but the marginal increase in total
costs between CFT and ceftriaxone was reduced to 4.6%.
Simulating the combination of CFT and ceftriaxone with a
macrolide marginally increased the total costs per patient
(e5,917.13 and e5,684.98 respectively) compared to the base
Table 2. Economic inputs for the cost-consequences analysis.
Health care resource use Average value (SE) Distribution Reference
Mean hospital LOS (95% CI) initial antibiotic treatment success (days) 11.3 (0.24) Normal 23
Mean hospital LOS (95% CI) initial antibiotic treatment failure (days) 15.3 (0.5) Normal 23
Proportion of treatment failures admitted to ICU 19.8% (1.57%) Beta 23
Duration of ICU stay (days) 10.9 (0.51) Normal 23
Proportion of patients eligible for IV-to-oral therapy 44% (3.51%) Beta 22
Duration of antibiotic treatment (days) 6.6 1 16
Duration of second-line antibiotic treatment (days) 7 1 Assumption
Unit costs Value (e 2017) Reference
Hospital day stay (per day) 553.90 Spanish National Price List30
ICU stay (per day) 1,456.52
Drug Acquisition Costs (per unit/per day)
Ceftaroline 600mg q12hr 60.00/120.00
Ceftriaxone 1 g q24hr 3.89/3.89
Co-amoxiclav 1.2 g q8hr 4.0/12.0
Moxifloxacin 400mg q24hr 31.2/31.2
Levofloxacin 500mg q24hr 12.15/12.15
Oral Step-down Antibiotic (co-amoxiclav) 4.0/12.0
Second-line antibiotic in general ward (ceftriaxone) 3.89/3.89
Second-line antibiotic in ICU (ceftriaxoneþ azithromycin) 10.86/10.86
Abbreviations. CI, confidence interval; ICU, intensive care unit; IV, intravenous; LOS, length of stay; q8hr, every eight hours; q12hr, every
12 hours; q24hr, every 24 hours; SE, standard error.
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case results (see Table 4) without impacting the incremental
total costs per patient (since the same macrolide treatment
was added to both comparators).
When the analysis was restricted to patients with
pneumococcal pneumonia, CFT was estimated to be cost-
saving versus ceftriaxone (1 g q24hr), with a total cost reduc-
tion of e54.63 per patient (Table 4). Despite higher projected
initial antibiotic and oral antibiotic step-down costs, those
associated with hospitalization and second-line antibiotics
were predicted to be lower with CFT. More patients achieved
initial antibiotic treatment success with CFT than ceftriaxone
(63.97% versus 61.54%), and more CFT patients would be
early discharged than ceftriaxone (32.1% versus 24.6%).
Considering a higher dosage of ceftriaxone (2 g q24hr)
resulted in higher cost-savings of e74.62 per patient while
adding macrolide concomitant therapy to CFT and ceftriax-
one did not impact the per-patient costs savings.
CFT was also predicted to be cost-saving overall versus
levofloxacin 500mg q24hr (e354.33 per patient), mainly
ascribable to the relatively high Day 4 response rate which
resulted in reduced length of hospital stay (Table 4). Indeed,
in comparison with levofloxacin, CFT increased the percent-
age of early discharges (30.6% vs. 14.96%) and decreased ini-
tial antibiotic failures (4.8% vs. 13%) and number of patients
Figure 2. Comparison of total costs per patient (left side) and the percentage of patients discharged early (right side) for CFT, Ceftriaxone, and Levofloxacin.
Abbreviations. CFT, ceftaroline fosamil; q12hr, every 12 hours; q24hr, every 24 hours
Table 3. Total and incremental percentage of patients, for each treatment pathway (according to Figure 1), predicted by the model.
All pneumonias Pneumococcal pneumonia
CFT Ceftriaxone Levofloxacin CFT Ceftriaxone
Total
(%)
Total
(%)
Incremental
vs. CFT (%)
Total Incremental
vs. CFT
Total
(%)
Total
(%)
Incremental
vs. CFT (%)
Initial antibiotic treatment success. Patient remains on initial
antibiotic to complete IV course of therapy. (Pathway
Aþ Pathway C)
64.63 64.38 0.25 72.03 7.4% 63.97 61.54 2.43
Initial antibiotic treatment success. Clinical response achieved
at Day 4. Patients switched to oral antibiotic and
discharged early (Pathway B)
30.58 26.14 4.44 14.96 15.62% 32.12 24.64 7.48
Initial antibiotic treatment failure. Patients switched to
second-line antibiotic and managed in general ward
(Pathway D)
3.84 7.61 3.77 10.44 6.6% 3.14 11.08 7.94
Initial antibiotic treatment failure. Patients switched to
second-line antibiotic and managed in ICU (Pathway E)
0.95 1.88 0.93 2.58 1.63 0.78 2.74 1.96
Abbreviations. CFT, ceftaroline fosamil; ICU, intensive care unit; IV, intravenous.
Table 4. Total and incremental hospital costs per patient by antibiotic regimen and pneumonia type.
All Pneumonias (e 2017) Pneumococcal pneumonia (e 2017)
CFT Ceftriaxone Levofloxacin CFT Ceftriaxone
Total Total Incremental vs. CFT Total Incremental vs. CFT Total Total Incremental vs. CFT
Total average hospital cost e5,929.59 e5,643.49 e286.10 e6,283.92 e2354.33 e5,829.77 e5,884.40 e254.63
Initial antibiotic therapy e681.65 e22.07 e659.58 e71.36 e610.29 e679.57 e21.78 e657.79
Oral antibiotic step-down e24.22 e20.70 e3.52 e11.85 e12.37 e25.44 e19.51 e5.92
Second-line antibiotic e1.77 e3.50 e1.73 e4.80 e3.03 e1.44 e5.10 e3.65
Hospital stay (general ward) e5,071.43 e5,299.04 e227.61 e5,786.91 e715.48 e5,000.25 e5,403.71 e403.46
Hospital stay (ICU) e150.52 e298.18 e147.65 e409.01 e258.48 e123.07 e434.30 e311.23
Abbreviations. CFT, ceftaroline fosamil; ICU, intensive care unit.
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treated in ICU (0.9% vs. 2.6%) (see Table 3). Increasing levo-
floxacin dosage (1 g q24hr) increased total cost savings per
patient, predicted by the model, to e425.68 while adding
concomitant macrolide therapy to CFT reduced the cost sav-
ings per patient to e312.79.
Threshold analysis indicated that total cost neutrality with
respect to CFT was achieved with an early response rate of
53.63% and 54.24% for moxifloxacin and co-amoxiclav
respectively. Considering concomitant macrolide therapy
with the beta-lactams (CFT and co-amoxiclav) marginally
reduced moxifloxacin early response rate for achieving cost
neutrality to 52.1% while had no impact on CFT/co-amoxiclav
comparison.
Finally, consistently with the literature, the model demon-
strated that antibiotic costs represent a small proportion of
overall hospital costs (<11% of total costs), the main driver
being hospital length of stay (>85% of total costs).
Sensitivity analyses
The deterministic sensitivity analyses, where each input par-
ameter was varied separately as the lower and upper bound
of the corresponding confidence interval (see Table 1), dem-
onstrated that day 4 responses, clinical cure rates and anti-
biotic treatment duration were the key drivers of total costs,
when comparing CFT with ceftriaxone (see Figure 3(a)).
Similarly, the top-three parameters generating the most vari-
ation in total costs when comparing CFT with levofloxacin
were day 4 responses and the risk ratio of clinical cure rates,
as highlighted in Figure 3(b). The full list of per patient incre-
mental cost obtained setting each model parameter to the
lower and upper bound of the confidence interval is pre-
sented in Figure 3(a) with respect to ceftriaxone and in
Figure 3(b) with respect to levofloxacin.
Threshold analysis was repeated for moxifloxacin and co-
amoxiclav using the lower and upper bounds of the risk ratio
confidence intervals (see Table 1). Varying the moxifloxacin
and co-amoxiclav risk ratios to the lower and upper bounds
of the confidence interval resulted in an early response rate
of 48–57.2% and 48.3–58.1%, respectively, for achieving cost-
neutrality with respect to CFT.
The probabilistic sensitivity analysis, during which the cost
and clinical inputs were simultaneously varied by random
sampling from the input distributions (see Tables 1 and 2)
demonstrated that CFT reduced the total cost in 90.9% of
the cases compared with levofloxacin and in 3% of the cases
compared with ceftriaxone.
Discussion
With an aging population, the incidence of CAP and in turn
the associated economic burden will continue to rise in the
coming years3. Given the rising amount of treatments avail-
able to clinicians and the fact that treatment decisions will
be based upon both clinical and economic factors, this mod-
elling study was undertaken to compare the cost and conse-
quences of using CFT in hospitalized adults with moderate
to severe CAP with respect to alternative antibiotics com-
monly used.
The greater early treatment success with CFT compared
with ceftriaxone was associated with a reduction in costs for
second line antibiotic and hospitalization. However, these
Figure 3. Deterministic sensitivity analysis results: CFT 600mg q12hr versus Ceftriaxone 1 g q24hr (a); CFT 600mg q12hr versus Levofloxacin 500mg q24hr (b).
Abbreviations. ABT, antibiotic therapy; CFT, ceftaroline fosamil; LOS, length of stay; q12hr, every 12 hours; q24hr, every 24 hours.
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cost savings were insufficient to offset the higher CFT drug
acquisition and infusion costs; resulting in a marginal (<5%)
increase in total costs versus ceftriaxone (1–2 g q24hr).
Nevertheless, the model predicted that in responding
patients more would be discharged early with CFT than cef-
triaxone. Furthermore, in the pneumococcal pneumonia sub-
group analysis, CFT treatment resulted cost-saving while
significantly increasing the number of patients achieving ini-
tial antibiotic treatment success and early discharge. This
would suggest that CFT may be preferred to ceftriaxone in
hospitalized adults with suspected pneumococcal pneumo-
nia, which is one of the main causative organisms of CAP3.
When compared against levofloxacin, the model demon-
strated that CFT would result in significant cost savings per
patient, due to greater clinical efficacy resulting in decreased
initial antibiotic treatment failures and increased percentage
of early discharges.
The sensitivity analysis demonstrated that early response,
treatment duration and length of hospitalization are the key
drivers of total costs, which is consistent with what has been
previously described in the literature13. Furthermore, the
model demonstrates that antibiotic costs represent a small
proportion of overall hospital costs, the main driver being
hospital LOS3,13. This may be of benefit in focusing payers’
attention away from pharmacy spend alone towards a review
of the overall economic burden of managing patients with
moderately severe CAP in their hospital.
The developed model has multiple limitations. Firstly,
except for ceftriaxone, there are no head to head clinical tri-
als comparing CFT with the other antibiotics; thus, the clin-
ical inputs were based on available literature (see Table 1)
and indirect comparison (NMA)25 validated by clinical expert
opinion. Furthermore, significantly different criteria used to
measure early response data (Day 4) were observed in the
literature, which hampered comparisons with moxifloxacin
and co-amoxiclav (see Section 2.2.1). Secondly, the treatment
length has been assumed equal between CFT and all the
comparators (see Table 2), given the lack of evidence in lit-
erature. Given that this parameter is one of the key driver of
total costs, especially when comparing CFT with ceftriaxone
(see Figure 3(a)), further studies leveraging real-world evi-
dence regarding average length of treatment for each of the
considered comparators might be of interest. Thirdly, anti-
biotic dosage used in the clinical trials differs to the dosage
used in clinical practice. Multiple scenarios with increased
antibiotic dosage demonstrated a limited impact of the dos-
age variations with respect to the model outcomes and con-
clusions. However, the clinical efficacy was assumed to
remain constant due to the lack of literature evidence.
Fourthly, the unit costs used in the analysis (see Table 2)
could change in the future due to the introduction of
generics and do not take into considerations confidential dis-
counts provided by the manufacturers. Therefore, these two
aspects along with other considerations (e.g. changes in rec-
ommended dosages) will dictate modified cost-consequences
results. Finally, susceptibility rates were not considered in the
analysis, which might be a critical factor in countries with
high levels of emerging antibiotic resistance3,29. Specifically,
different types of causative organisms for CAP would have
different susceptibility patterns with respect to each of the
antimicrobial agents commonly used29, in turn affecting the
clinical efficacy of each treatment. On one hand, this would
require additional data regarding country-specific susceptibil-
ity patterns along with organism-specific clinical inputs for
each comparator included in the analysis, thus significantly
increasing the complexity of the analysis. On the other hand,
this could be of significant interest for future analyses, given
that the diverse nature of resistance across Europe highlights
the need of developing national guidelines to provide opti-
mal treatment3.
Conclusion
In conclusion, despite a higher unit cost, ceftaroline fosamil
is a reasonable alternative to other agents in the treatment
of adults hospitalized with moderate/severe CAP, given the
projected higher rate of patients discharged early achieved
with similar or lower total costs than the alternative treat-
ments considered.
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